New drug zanzalintinib aims to shrink thyroid tumors before surgery

NCT ID NCT06959511

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 4 times

Summary

This phase 2 trial tests the drug zanzalintinib given before surgery in 45 people with advanced thyroid cancer. The goal is to see if the drug can shrink tumors, making surgery more effective. Researchers will also monitor safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanzalintinib
What this could lead to: If successful, this could show that zanzalintinib shrinks advanced thyroid tumors before surgery, potentially improving outcomes.
What could go wrong: This is a small, early-phase trial (45 people) with no control group. The drug may not work or could cause side effects. Results may not apply to all thyroid cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma medullary thyroid gland carcinoma poorly differentiated thyroid gland carcinoma thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOADJUVANT TREATMENT THYROID CANCER

Contacts and locations

Locations

Cleveland Clinic Taussig Cancer Institute
RECRUITING

Cleveland, Ohio, 44195, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.